Symbol | Exchange | Currency |
|---|
Jaguar Health rises on Street high target from CantorJaguar Health (JAGX) hasrisen ~15.4%in early trading after Cantor Fitzgerald began the coverage with an overweight rating
Jaguar Health (JAGX): Q1 GAAP EPS of -$0.10 misses by $0.08.Revenue of $1.24M (+42.5% Y/Y) misses by $6.13M.Non-GAAP EBITDA loss was $9.0M vs. vs
Investors always look for stocks with low P/E ratios as the measure indicates undervaluation. This ratio is obtained by dividing a stock’s current market price with its...
We are initiating research on Jaguar Health Inc (NASDAQ:JAGX), which is centered on the development and marketing of its drug crofelemer for diarrheal disorders. It is approved and...
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Sell | Strong Sell | Strong Sell | Strong Sell | Sell |
| Technical Indicators | Strong Sell | Strong Sell | Strong Sell | Sell | Sell |
| Summary | Strong Sell | Strong Sell | Strong Sell | Strong Sell | Sell |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 2,715.60 | 2,733.20 | 2,710.90 | -6.3 | -0.23% | 1.59M | NASDAQ | |||
| 358.32 | 365.52 | 356.74 | -14.96 | -4.01% | 33.41M | NASDAQ | |||
| 197.54 | 201.14 | 194.91 | +1.53 | +0.78% | 23.36M | NYSE | |||
| 53.70 | 54.10 | 53.32 | +0.63 | +1.19% | 16.89M | NASDAQ | |||
| 118.87 | 119.13 | 118.14 | +0.32 | +0.27% | 4.63M | NYSE | |||
| 196.62 | 198.53 | 193.28 | +1.59 | +0.82% | 19.08M | NASDAQ | |||
| 461.23 | 461.75 | 454.77 | +7.15 | +1.57% | 287.17K | NYSE | |||
| 18.29 | 21.99 | 18.19 | -3.07 | -14.37% | 5.04M | NASDAQ | |||
| 10.64 | 10.99 | 10.52 | +0.12 | +1.14% | 15.34M | NYSE | |||
| 15.37 | 15.54 | 15.25 | +0.06 | +0.39% | 580.20K | NYSE | |||
| 52.72 | 53.69 | 51.25 | +1.72 | +3.37% | 782.74K | NYSE | |||
| 72.04 | 76.50 | 70.35 | -4.61 | -6.01% | 27.09M | NYSE | |||
| 11.49 | 11.64 | 11.47 | -0.02 | -0.17% | 7.35M | NASDAQ | |||
| 34.71 | 40.25 | 33.38 | -3.29 | -8.66% | 100.00M | NASDAQ | |||
| 42.54 | 43.07 | 41.62 | +1.30 | +3.15% | 1.78M | NYSE |
Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. It operates through two reportable segments, Human Health and Animal Health. The company, through its subsidiary, Napo Pharmaceuticals, Inc., focuses on developing and commercializing proprietary plant-based human gastrointestinal pharmaceuticals from plants harvested responsibly from rainforest areas. It markets Mytesi, a crofelemer 125 mg delayed-release tablet for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. It develops Mytesi for multiple possible follow-on indications, including diarrhea related to targeted cancer therapy; orphan-drug indications for infants and children with congenital diarrheal disorders and short bowel syndrome; supportive care for inflammatory bowel disease; irritable bowel syndrome; and for idiopathic/functional diarrhea, as well as a second-generation proprietary anti-secretory agent is in development for cholera. The company also develops Crofelemer, a drug product candidate for chemotherapy-induced diarrhea in dogs. Jaguar Health, Inc. was incorporated in 2013 and is headquartered in San Francisco, California.
